ANG-3586 - CYP Inhibitors Program
Through molecular modeling and rational drug design, we have built a proprietary platform to create highly specific libraries of inhibitors of cytochrome P450 (“CYP”) enzymes. The cytochrome P450 family of proteins includes enzymes responsible for the metabolism of drugs and ingested toxic substances and enzymes responsible for the metabolism of endogenous substances such as steroids, vitamins and lipids. We have modified and tailored our compounds for selectivity to inhibit specific enzymes. By thus modulating the activity of specific endogenous signal transduction pathways, we have the opportunity to target different diseases in which those pathways are implicated.
Our most advanced CYP inhibitor program is a CYP11B2 (aldosterone synthase) inhibitor, ANG-3586, which is being evaluated as a potential treatment for chronic kidney disease. It is selective for aldosterone synthase and has shown activity in preclinical animal models.
Another Angion CYP inhibitor targets CYP26, retinoic acid hydroxylase. This CYP is responsible for metabolizing retinoic acid, an endogenous molecule with beneficial activities in many diseases as well as maintaining the integrity of skin. Retinoic acid is present in some anti-wrinkle creams, but it has toxic side effects. By inhibiting CYP26 in the skin, the body’s endogenous levels of retinoic acid can be elevated to benefit the skin without the side effects of applied retinoic acid. Angion licensed the rights to one CYP26 inhibitor, ANG-3522, to a privately-held dermatology company for use in dermatological indications, in both cosmetic and prescription products.